Pathology & Laboratory Medicine

Warning message

Selective filter "Related Faculty (field_biblio_faculty) (selective)" has limited the amount of total results. Please, review you query configuration.

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Sparano JA, Lee JY, Kaplan LD, Ramos JC, Ambinder RF, Wachsman W, et al. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. Haematologica. 2021;106(3):730-735.

Costa V, Zhao Z, Racine-Brzostek SE, Lalazar G, Yang HS. An Interesting Case of Isolated False-Reactive Hepatitis B Surface Antigen. Case Reports Hepatol. 2021;2021:9928098.

Gomes C, Zuniga M, Crotty KA, Qian K, Tovar NC, Lin LH, et al. Autoimmune anti-DNA and anti-phosphatidylserine antibodies predict development of severe COVID-19. Life Sci Alliance. 2021;4(11).

Oh H, Hwang I, Jang J-, Wu L, Cao D, Yao J, et al. Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling. Cancer Res. 2021;81(6):1528-1539.

Egan CE, Stefanova D, Ahmed A, Raja VJ, Thiesmeyer JW, Chen KJ, et al. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer. Thyroid. 2021.

Tabbo F, Guerrera F, van den Berg A, Gaudiano M, Maletta F, Bessone L, et al. Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways. Eur J Cancer. 2021;144:17-30.

De Piano M, Manuelli V, Zadra G, Loda M, Muir G, Chandra A, et al. Exploring a role for fatty acid synthase in prostate cancer cell migration. Small GTPases. 2021;12(4):265-272.

Gaffney C, Liu D, Cooley V, Ma X, Angulo C, Robinson B, et al. Tumor size and genomic risk in localized prostate cancer. Urol Oncol. 2021;39(7):434.e17-434.e22.

Racine-Brzostek SE, Karbaschi M, Gaebler C, Klasse PJ, Yee J, Caskey M, et al. TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. Clin Chem. 2021;67(9):1249-1258.

Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2(4):444-456.